New Drug Monitoring Assay | Vedolizumab (Entyvio®) (mAb-based) ELISA
Posted by Brandon Savela on Jun 23rd 2017
We are pleased to introduce our latest addition to our Drug Monitoring Assay Line - Vedolizumab (Entyvio®) (mAb-based) ELISA!
The drug Vedolizumab (trade name Entyvio®) is a humanized immunoglobulin G1 monoclonal antibody that binds exclusively to the lymphocyte integrin α4β7. Identification of biomarkers might be beneficial for (non-) response and risk factors for adverse drug reactions that might be related to serum drug levels and maintaining the effective concentration in order to potentially avoid some side effects with a reliable method. The specificity of this testsystem is achieved by using a monoclonal antibody named "IG-19F3" for the coating of the microtiter plate. This antibody is specific for Vedolizumab only and does not cross react with other lymphocyte integrin α4β7 catchers.
Enzyme immunoassay for the specific determination of free Vedolizumab in serum and plasma. For research use only - not for use in diagnostic procedures.
| Catalog Number | IG-AB116 |
|---|---|
| Species | Human |
| Design | Enzyme immunoassay (ELISA) technique. |
| Standards | 5 standards, ready to use. |
| Controls | None provided. |
| Sample Types | Serum and plasma. |
| Sample Volume | 10 µL |
| Assay Desc. | 1 hour incubation (RT) + 30 min. (RT) + 20 min. (RT) = 1 hour, 50 min. total incubation time. |
| Standard Range | 0 / 6 - 200 ng/mL |
| Sensitivity | 5 ng/mL |
Contact us for more information
